Cover Image
市場調查報告書

冷凍乾燥注射劑市場

Lyophilized Injectables to 2020

出版商 Greystone Research Associates 商品編碼 322745
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
冷凍乾燥注射劑市場 Lyophilized Injectables to 2020
出版日期: 2016年01月01日 內容資訊: 英文
簡介

本報告提供冷凍乾燥注射劑概要和適應治療、冷凍乾燥技術與市場發展趨勢、到2020年的預測、加入此市場的主要企業簡介等彙整資料。

摘要整理

市場機會

  • 給藥市場趨勢
  • 冷凍乾燥藥物的經濟性
  • 所謂促進冷凍乾燥藥物市場的東西
  • 自我施打趨勢
  • 人口統計的變遷
  • 拋棄式設備設計的技術創新
  • 治療需求促進要素
  • 競爭環境
  • 風險係數

冷凍乾燥藥物:一次包裝

  • 單回使用小瓶
  • 照護現場重組
  • 特殊包裝
  • SC/IM注射劑
  • 吸入用藥物
  • 產品固有的設備

冷凍乾燥藥物:重組和給藥

  • 預填稀釋劑注射器
  • 專用重組設備
  • 單回階段設備
  • 多階段設備
  • 人因工程/人體工學

冷凍乾燥藥物:主要的治療領域分析與市場資料

  • 抗生素
  • 自體免疫疾病
  • 血液因子
  • 荷爾蒙
  • 感染疾病
  • 代謝障礙
  • 腫瘤
  • 再生醫療
  • 其他的治療層級
  • 市場因素
  • 法律規章的課題
  • 患者的適合性與易用性
  • 醫療經濟學

簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LPJ297D

Evolution in Drug Formulations

The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the ‘cold chain'. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection.

‘The number of drugs supplied in lyophilized form has been growing at an increased rate over the past several years, mirroring the increase in the introduction of biological drugs. For lyophilized drugs intended for self-administration, reconstitution must occur at the point of use. This report analyzes more than 450 drugs that are supplied in powder form and require reconstitution prior to administration'


Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

What You Will Learn

  • Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
  • Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
  • Analyzes lyophilization technologies and market development issues
  • Provides market data and forecasts to 2020
  • Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of technology and regulatory factors on commercialization and market access

Table of Contents

  • Executive Summary
  • The Market Opportunity
  • Delivery Market Dynamics
  • The Economics of lyophilized Drugs
  • What's Driving the Market for Lyophilized Drugs?
    • The Trend toward Self-Administration
    • Shifting Demographics
    • Innovation in Disposable Device Designs
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors
  • Lyophilized Drugs - Primary Packaging
  • Single Use Vials
  • Point-of-Care Reconstitution
  • Specialty Packaging
    • Drugs for SC/IM Injection
    • Drugs for Infusion
  • Product Specific Devices
  • Lyophilized Drugs - Reconstitution and Delivery
  • Prefilled Diluent Syringes
  • Proprietary Reconstitution Devices
  • Single Step Devices
  • Multi-Step Devices
  • Human Engineering/Ergonomics
  • Lyophilized Drugs - Key Therapeutic Sector Analysis and Market Data
  • Antibiotics
  • Autoimmune Diseases
  • Blood Factors
  • Hormones
  • Infectious Diseases
  • Metabolic Conditions
  • Oncology
  • Reproductive Health
  • Other Important Therapeutic Classes
  • Market Factors
  • Regulatory Issues
  • Patient Compliance and Ease of Use
  • Healthcare Economics
  • Company Profiles
Back to Top